Localization | 2020.09.22
Kemp Proteins Selected to Provide Assay Development for Potential First-In-Class Therapy for Chronic Spinal Cord Injury
Subcontract award by the Frederick National Laboratory, currently operated by Leidos Biomedical Research, Inc. as part of NIH’s National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program to assist ReNetX Bio’s AXER-204 FDA trial to promote recovery of neurological function in spinal cord injury patients
(PRWeb September 22, 2020)
Read the full story at https://www.prweb.com/releases/kemp_proteins_selected_to_provide_assay_development_for_potential_first_in_class_therapy_for_chronic_spinal_cord_injury/prweb17401594.htm
For more information, please visit
https://www.prweb.com/releases/kemp_prot[...]_cord_injury/prweb17401594.htm
Instagram is adding automatic in-app text translation - The Verge views: 1599
Instagram is adding automatic in-app text translation - The Verge views: 1509